Trials / Conditions / Recurrent Childhood Grade III Lymphomatoid Granulomatosis

Recurrent Childhood Grade III Lymphomatoid Granulomatosis

25 registered clinical trials studyying Recurrent Childhood Grade III Lymphomatoid Granulomatosis.

Status	Trial	Sponsor	Phase
Completed	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477	Case Comprehensive Cancer Center	EARLY_Phase 1
Completed	MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT01748721	Morphotek	Phase 1
Completed	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916	University of Chicago	Phase 2
Completed	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827	Roswell Park Cancer Institute	Phase 2
Completed	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881	Fred Hutchinson Cancer Center	Phase 2
Completed	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919	National Cancer Institute (NCI)	Phase 1
Completed	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494	Wake Forest University Health Sciences	N/A
Terminated	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent NCT00994500	National Cancer Institute (NCI)	Phase 1
Terminated	Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985	National Cancer Institute (NCI)	Phase 1
Completed	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refracto NCT00867529	Fred Hutchinson Cancer Center	Phase 2
Completed	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388	Roswell Park Cancer Institute	N/A
Completed	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586	Case Comprehensive Cancer Center	Phase 2
Completed	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601	Roswell Park Cancer Institute	N/A
Completed	Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma NCT00363272	National Cancer Institute (NCI)	Phase 1
Completed	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798	Fred Hutchinson Cancer Center	Phase 1
Completed	Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, NCT00217412	National Cancer Institute (NCI)	Phase 1
Completed	Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270	National Cancer Institute (NCI)	Phase 1
Completed	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352	Fred Hutchinson Cancer Center	Phase 2
Terminated	Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205	National Cancer Institute (NCI)	Phase 1
Completed	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011	Fred Hutchinson Cancer Center	Phase 2
Completed	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504	Fred Hutchinson Cancer Center	Phase 2
Completed	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235	Fred Hutchinson Cancer Center	N/A
Completed	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251	Fred Hutchinson Cancer Center	Phase 1 / Phase 2